Supplementary Figure S3 from Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients
Authors:
Open Access
- 5 January 2024
- other
- Published by American Association for Cancer Research (AACR)